Market Access BIO Boston: 2025 is shaping up to be a year of challenge – b... What were the major themes to come out of BIO Boston 2025? Despite global events in the background, a fair amount of positivity.
Market Access One in five expressions of interest in UK regulator's pilot ... The MHRA, will be running five pilot dialogues as part of its first year exploring a real-world evidence scientific dialogue programme.
Market Access Balancing efficiency with risks: How biopharma companies can... AI technologies can enable companies to program, rather than write, submissions to health authorities.
Market Access Biotech opportunities in North Carolina, with Kyle Touchston... From BIO 2025: Kyle Touchstone, director of Economic Development Raleigh and Laura Rowley, director of life sciences development for NCBiotech.
Market Access Four months, 157 Executive Orders: Inside the science of Tru... When Donald Trump returned to the White House in January 2025, the question wasn't whether his administration would change the direction of US health policy – it was how quickly, how deeply
Market Access The changing landscape of drug clinical assessment: Tommy Br... In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face